Hidden players of COVID-19: the evolving roles of SARS-CoV-2 accessory proteins.

Hidden players of COVID-19: the evolving roles of SARS-CoV-2 accessory proteins.

Publication date: Oct 16, 2025

SARS-CoV-2 accessory proteins (APs), particularly ORF3a and ORF9b, have emerged as key modulators of host-pathogen interaction and potential contributors to long COVID. Of the 13 predicted APs, only nine are expressed during infection – termed Infection-related APs – while the remaining are classified as Putative APs. Despite this distinction, extensive gene overlap among APs underscores the remarkable adaptability of SARS-CoV-2 viral genome. This review delves into the diverse roles of the original Wuhan APs and their Omicron counterparts in shaping host immunity, with an emphasis on their ability to suppress type I interferon (IFN-I) signalling, modulate cellular metabolism, and trigger inflammatory/apoptotic pathways. By integrating immunopathological insights with evolutionary dynamics and structural perspectives, this review provides a comprehensive understanding of the mechanism underlying Omicron’s reduced pathogenicity and highlights promising, yet unexplored, therapeutic targets within the SARS-CoV-2 accessory proteome.

Open Access PDF

Concepts Keywords
Adaptability accessory proteins
Apoptotic Animals
Genome COVID-19
Immunopathological COVID-19
Viral Host-Pathogen Interactions
Humans
Interferon Type I
Interferon Type I
omicron lineages
SARS-CoV-2
SARS-CoV-2
viral pathobiology
Viral Proteins
Viral Proteins

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Adenosine 5′-phosphosulfate
disease MESH long COVID
disease MESH infection
pathway REACTOME Metabolism
pathway REACTOME Reproduction
disease MESH Zoonoses
drug DRUGBANK Angiotensin II
pathway REACTOME Apoptosis
disease MESH influenza
pathway KEGG Ribosome
pathway REACTOME Translation
disease MESH immune Suppression
disease MESH PRRs
disease MESH OAS
drug DRUGBANK Trimebutine
drug DRUGBANK Amino acids
drug DRUGBANK L-Leucine
drug DRUGBANK Isoxaflutole
pathway KEGG Proteasome
pathway REACTOME Mitophagy
disease MESH included
disease MESH viral infections
drug DRUGBANK Coenzyme M
drug DRUGBANK Methionine
disease MESH inflammation
drug DRUGBANK Oxygen
pathway REACTOME Release
disease MESH STING
disease MESH death
pathway REACTOME Pyroptosis
disease MESH cytokine storm
disease MESH pulmonary fibrosis
drug DRUGBANK L-Cysteine
pathway KEGG Viral replication
drug DRUGBANK ATP
drug DRUGBANK Potassium
disease MESH mitochondrial dysfunction
pathway KEGG Ferroptosis
drug DRUGBANK Myricetin
pathway REACTOME Glycolysis
drug DRUGBANK Dextrose unspecified form
disease MESH hypoxia
drug DRUGBANK Calcium
disease MESH OPA1
pathway REACTOME Autophagy
pathway KEGG Lysosome
pathway KEGG Oxidative phosphorylation
pathway REACTOME Fatty acid metabolism
disease MESH lung inflammation
pathway REACTOME Potassium Channels
disease MESH fatigue
disease MESH injury
disease MESH strain
disease MESH coronavirus infection
disease MESH PDD
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH severe acute respiratory syndrome
pathway REACTOME Interferon Signaling
drug DRUGBANK Guanosine
pathway KEGG Nucleocytoplasmic transport
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH David
disease MESH AAA
disease MESH Chai
disease MESH SAPHO syndrome
drug DRUGBANK N-acetylsulfanilyl chloride
drug DRUGBANK Anakinra
disease MESH Allergy
disease MESH Lam
drug DRUGBANK Carboxyamidotriazole
disease MESH Lung Injury
pathway REACTOME Glucose metabolism
drug DRUGBANK Succinic acid
disease MESH Rai
disease MESH lfs
drug DRUGBANK Nitroglycerin
drug DRUGBANK Glycerol phenylbutyrate
disease MESH Papa
disease MESH clinical progression
pathway KEGG Homologous recombination
disease MESH syndrome

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *